These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

369 related articles for article (PubMed ID: 24566314)

  • 21. Blood Molecular Genomic Analysis Predicts the Disease Course of Gastroenteropancreatic Neuroendocrine Tumor Patients: A Validation Study of the Predictive Value of the NETest®.
    van Treijen MJC; van der Zee D; Heeres BC; Staal FCR; Vriens MR; Saveur LJ; Verbeek WHM; Korse CM; Maas M; Valk GD; Tesselaar MET
    Neuroendocrinology; 2021; 111(6):586-598. PubMed ID: 32492680
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Advances of circulating biomarkers in gastroenteropancreatic neuroendocrine neoplasms].
    Chen L; Chen M; Chen J
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Mar; 20(3):357-360. PubMed ID: 28338171
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gastroenteropancreatic neuroendocrine tumors: Epigenetic landscape and clinical implications.
    McMurry HS; Rivero JD; Chen EY; Kardosh A; Lopez CD; Pegna GJ
    Curr Probl Cancer; 2024 Oct; 52():101131. PubMed ID: 39173542
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel preclinical gastroenteropancreatic neuroendocrine neoplasia models demonstrate the feasibility of mutation-based targeted therapy.
    Viol F; Sipos B; Fahl M; Clauditz TS; Amin T; Kriegs M; Nieser M; Izbicki JR; Huber S; Lohse AW; Schrader J
    Cell Oncol (Dordr); 2022 Dec; 45(6):1401-1419. PubMed ID: 36269546
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A precision oncology approach to the pharmacological targeting of mechanistic dependencies in neuroendocrine tumors.
    Alvarez MJ; Subramaniam PS; Tang LH; Grunn A; Aburi M; Rieckhof G; Komissarova EV; Hagan EA; Bodei L; Clemons PA; Dela Cruz FS; Dhall D; Diolaiti D; Fraker DA; Ghavami A; Kaemmerer D; Karan C; Kidd M; Kim KM; Kim HC; Kunju LP; Langel Ü; Li Z; Lee J; Li H; LiVolsi V; Pfragner R; Rainey AR; Realubit RB; Remotti H; Regberg J; Roses R; Rustgi A; Sepulveda AR; Serra S; Shi C; Yuan X; Barberis M; Bergamaschi R; Chinnaiyan AM; Detre T; Ezzat S; Frilling A; Hommann M; Jaeger D; Kim MK; Knudsen BS; Kung AL; Leahy E; Metz DC; Milsom JW; Park YS; Reidy-Lagunes D; Schreiber S; Washington K; Wiedenmann B; Modlin I; Califano A
    Nat Genet; 2018 Jul; 50(7):979-989. PubMed ID: 29915428
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systemic treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETS): current approaches and future options.
    Strosberg JR
    Endocr Pract; 2014 Feb; 20(2):167-75. PubMed ID: 24014009
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Models of Gastroenteropancreatic Neuroendocrine Neoplasms: Current Status and Future Directions.
    Detjen K; Hammerich L; Özdirik B; Demir M; Wiedenmann B; Tacke F; Jann H; Roderburg C
    Neuroendocrinology; 2021; 111(3):217-236. PubMed ID: 32615560
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Irinotecan plus cisplatin followed by octreotide long-acting release maintenance treatment in advanced gastroenteropancreatic neuroendocrine carcinoma: IPO-NEC study.
    Li J; Lu M; Lu Z; Li Z; Liu Y; Yang L; Li J; Zhang X; Zhou J; Wang X; Gong J; Gao J; Li Y; Shen L
    Oncotarget; 2017 Apr; 8(15):25669-25678. PubMed ID: 27788498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glutaminases in slowly proliferating gastroenteropancreatic neuroendocrine neoplasms/tumors (GEP-NETs): Selective overexpression of mRNA coding for the KGA isoform.
    Szeliga M; Ćwikła J; Obara-Michlewska M; Cichocki A; Albrecht J
    Exp Mol Pathol; 2016 Feb; 100(1):74-8. PubMed ID: 26581715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update.
    Kole C; Charalampakis N; Vailas M; Tolia M; Sotiropoulou M; Tsakatikas S; Kouris NI; Tsoli M; Koumarianou A; Karamouzis MV; Schizas D
    Cancer Immunol Immunother; 2022 Apr; 71(4):761-768. PubMed ID: 34471940
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The clinical utility of a novel blood-based multi-transcriptome assay for the diagnosis of neuroendocrine tumors of the gastrointestinal tract.
    Modlin IM; Kidd M; Bodei L; Drozdov I; Aslanian H
    Am J Gastroenterol; 2015 Aug; 110(8):1223-32. PubMed ID: 26032155
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intertumoral lineage diversity and immunosuppressive transcriptional programs in well-differentiated gastroenteropancreatic neuroendocrine tumors.
    Hoffman SE; Dowrey TW; Villacorta Martin C; Bi K; Titchen B; Johri S; DelloStritto L; Patel M; Mackichan C; Inga S; Chen J; Grimaldi G; Napolitano S; Wakiro I; Wu J; Yeung J; Rotem A; Sicinska E; Shannon E; Clancy T; Wang J; Denning S; Brais L; Besson NR; Pfaff KL; Huang Y; Kao KZ; Rodig S; Hornick JL; Vigneau S; Park J; Kulke MH; Chan J; Van Allen EM; Murphy GJ
    Sci Adv; 2023 Sep; 9(39):eadd9668. PubMed ID: 37756410
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chromogranin A: a sensitive biomarker for the detection and post-treatment monitoring of gastroenteropancreatic neuroendocrine tumors.
    Singh S; Law C
    Expert Rev Gastroenterol Hepatol; 2012 Jun; 6(3):313-34. PubMed ID: 22646254
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas.
    Garcia-Carbonero R; Sorbye H; Baudin E; Raymond E; Wiedenmann B; Niederle B; Sedlackova E; Toumpanakis C; Anlauf M; Cwikla JB; Caplin M; O'Toole D; Perren A;
    Neuroendocrinology; 2016; 103(2):186-94. PubMed ID: 26731334
    [No Abstract]   [Full Text] [Related]  

  • 35. Diagnostic and Predictive Role of DLL3 Expression in Gastroenteropancreatic Neuroendocrine Neoplasms.
    Liverani C; Bongiovanni A; Mercatali L; Pieri F; Spadazzi C; Miserocchi G; Di Menna G; Foca F; Ravaioli S; De Vita A; Cocchi C; Rossi G; Recine F; Ibrahim T
    Endocr Pathol; 2021 Jun; 32(2):309-317. PubMed ID: 33409812
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nordic guidelines 2021 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
    Janson ET; Knigge U; Dam G; Federspiel B; Grønbaek H; Stålberg P; Langer SW; Kjaer A; Arola J; Schalin-Jäntti C; Sundin A; Welin S; Thiis-Evensen E; Sorbye H
    Acta Oncol; 2021 Jul; 60(7):931-941. PubMed ID: 33999752
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
    Pavel M; Öberg K; Falconi M; Krenning EP; Sundin A; Perren A; Berruti A;
    Ann Oncol; 2020 Jul; 31(7):844-860. PubMed ID: 32272208
    [No Abstract]   [Full Text] [Related]  

  • 38. NET Blood Transcript Analysis Defines the Crossing of the Clinical Rubicon: When Stable Disease Becomes Progressive.
    Pavel M; Jann H; Prasad V; Drozdov I; Modlin IM; Kidd M
    Neuroendocrinology; 2017; 104(2):170-182. PubMed ID: 27078712
    [TBL] [Abstract][Full Text] [Related]  

  • 39. APOBEC3B High Expression in Gastroenteropancreatic Neuroendocrine Neoplasms and Association With Lymph Metastasis.
    Feng C; Zheng Q; Yang Y; Xu M; Lian Y; Huang J; Jiang Y
    Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):599-605. PubMed ID: 30095460
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Management of controversial gastroenteropancreatic neuroendocrine tumour clinical situations with somatostatin analogues: results of a Delphi questionnaire panel from the NETPraxis program.
    Sevilla I; Segura Á; Capdevila J; López C; García-Carbonero R; Grande E;
    BMC Cancer; 2016 Nov; 16(1):858. PubMed ID: 27821081
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.